NASDAQ · DYAIHealthcareBiotechnology

Dyadic International financials

$0.4660+0.22%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 31
FY24
Dec 31
FY23
Dec 31
FY22
Dec 31
FY21
Dec 31
FY20
Dec 31
FY19
Dec 31
Revenue$3.1M$3.5M$2.9M$2.9M$2.4M$1.6M$1.7M
Gross profit$770.5K$2.3M$923.0K$807.1K$459.4K$177.0K$221.4K
Gross margin24.9%65.8%31.8%27.5%19.1%11.0%13.2%
Operating income-$7.1M-$5.9M-$8.2M-$10.1M-$14.6M-$10.0M-$9.3M
Net income-$7.4M-$5.8M-$6.8M-$9.7M-$13.1M-$9.3M-$8.3M
Net margin−238.3%−166.2%−234.4%−332.2%−543.7%−582.1%−494.2%
Diluted EPS$-0.23$-0.20$-0.24$-0.34$-0.47$-0.34$-0.31
EBITDA-$7.2M-$5.9M-$8.2M-$10.1M-$14.3M-$9.6M-$9.1M
Operating cash flow-$5.7M-$4.0M-$6.7M-$8.1M-$11.3M-$6.6M-$5.8M
Free cash flow-$5.7M-$4.0M-$6.7M-$8.1M———
Diluted shares32.6M29.3M28.8M28.4M27.8M27.5M27.0M

Balance sheet

Period endDec 31Dec 31Dec 31Dec 31Dec 31Dec 31
Cash & equivalents$4.6M$6.5M$6.5M$5.8M$15.7M$20.6M
Short-term investments$2.7M$2.8M$748.3K$6.8M$4.5M$8.5M
Total debt$5.0M$3.9M$0.00$0.00$0.00$0.00
Total assets$9.9M$9.9M$8.2M$13.7M$21.3M$30.1M
Total liabilities$8.7M$7.5M$2.3M$2.6M$2.9M$1.6M
Shareholders' equity$1.2M$2.5M$5.9M$11.1M$18.4M$28.4M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology